Top > News Releases
 March 31, 2010 |
Y's Therapeutics Announced the change of the board members on March 31, 2010 |
| June 8, 2009 |
Y's Therapeutics Co., Ltd. appointed Susumu Yamada as board member&CBO, and Akira Murakami & Yoshihiro Ito as Auditors on June 8, 2009. |
| May 16, 2009 |
Y’s Therapeutics Co., Ltd have been reduced the paid-in capital and capital reserve. |
| March 31, 2009 |
Y's Therapeutics Announced the change of the board members on April 1, 2009 |
| January 8, 2009 |
An internet site, Science-Business eXchange which was managed by BioCentury and Nature published that YSPSL would be a potent anti-elilepsy drug. |
| November 5, 2008 |
Y’s Therapeutics Announces Acceptance of CTA to conduct Phase I/II Clinical Trial of YSCMA in France |
| September 16, 2008 |
Y's Therapeutics Completes Phase IIa Trial with YSPSL in Kidney Transplant Patients for Prevention of Ischemic Reperfusion Injury (IRI) |
| September 10, 2008 |
Conclusion of Exclusive Licensing Agreement of YSCMA, Humanized Anti-CD26 Monoclonal Antibody, for Development and Sales in Japan |
| February 14, 2008 |
Y's Therapeutics announces FDA acceptance of IND to conduct Phase I clinical trial for YSCMA in the USA |
| January 15, 2008 |
We have update the employment information at the our website. |
| November 1, 2007 |
Y's Therapeutics Appoints Takaharu Itoh as CFO on November 1, 2007 |
| August 1, 2007 |
Y's Therapeutics Announced the change of the board members on August 1, 2007 |
| May 2, 2007 |
Y's Therapeutics Initiates Phase II Trial with YSPSL in Liver Transplant Patients for Prevention of Ischemic Reperfusion (I/R) Injury |
| April 24, 2007 |
Y's Therapeutics Completes Enrollment of Phase II Trial in the U.S. With YSPSL for Prevention of Delayed Graft Function in Renal Transplantation |
| Oct 3, 2006 |
Y's Therapeutics Raises 2.3 billion yen (US $20 million) in Series D Financing |
| Jul 21, 2006 |
Y's Therapeutics Clinical-Stage Compound YSPSL Granted Orphan Status in U.S. and Europe |
| Feb 24, 2006 |
Y's Therapeutics appoints Nobuo kato as President and CEO, and Motoharu Higashizono as Board of Director and COO on Dec 22, 2005 |
| Nov 29, 2005 |
Y's Therapeutics Initiates Phase II Clinical Program to Evaluate YSPSL in Prevention of Delayed Graft Function |
| August 9, 2005 |
Y's Therapeutics Appoints Elizabeth Squiers, MD, FACS as Vice President for Clinical and Regulatory Affairs |
| Dec 20, 2004 |
Y's Therapeutics Raises 1.2 billion yen (US $11.3million) in Series C Financing |
| Oct 5, 2004 |
Y's Therapeutics Appoints John Wulf as Head of U.S. Operations and Global Chief Business Officer - Biotechnology Executive to Lead Worldwide Business Development Efforts - |
| Sept 27, 2004 |
Kissei Pharmaceutical Options Antibody from Y's Therapeutics |
| July 26, 2004 |
Y's Therapeutics Files to Begin Two Phase II Clinical Trials in Europe for Rheumatoid Arthritis and Asthma - Subsidiaries to be Established in Germany and US - |
| April 6, 2004 |
Y's Therapeutics and Lonza Announce Development/Manufacturing Agreement - Another Milestone for Y's YSCMA Program - |
| March 10, 2004 |
Notice of Change of Premises |
| March 2, 2004 |
Abmaxis and Y's Therapeutics Announce Antibody Collaboration - Therapeutic Focus on Tumors - |
| February 23, 2004 |
Y's Therapeutics Raises 2.4 billion yen (US $22 million) in Series B Financing - One of the Largest Private Equity Financings in Japanese Biotech Industry - |
Top | Site Map | Access Map | Privacy Policy | Terms of Use |
